Cargando…
STAT3 and STAT5 Activation in Solid Cancers
The Signal Transducer and Activator of Transcription (STAT)3 and 5 proteins are activated by many cytokine receptors to regulate specific gene expression and mitochondrial functions. Their role in cancer is largely context-dependent as they can both act as oncogenes and tumor suppressors. We review...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826753/ https://www.ncbi.nlm.nih.gov/pubmed/31557897 http://dx.doi.org/10.3390/cancers11101428 |
_version_ | 1783465165307510784 |
---|---|
author | Igelmann, Sebastian Neubauer, Heidi A. Ferbeyre, Gerardo |
author_facet | Igelmann, Sebastian Neubauer, Heidi A. Ferbeyre, Gerardo |
author_sort | Igelmann, Sebastian |
collection | PubMed |
description | The Signal Transducer and Activator of Transcription (STAT)3 and 5 proteins are activated by many cytokine receptors to regulate specific gene expression and mitochondrial functions. Their role in cancer is largely context-dependent as they can both act as oncogenes and tumor suppressors. We review here the role of STAT3/5 activation in solid cancers and summarize their association with survival in cancer patients. The molecular mechanisms that underpin the oncogenic activity of STAT3/5 signaling include the regulation of genes that control cell cycle and cell death. However, recent advances also highlight the critical role of STAT3/5 target genes mediating inflammation and stemness. In addition, STAT3 mitochondrial functions are required for transformation. On the other hand, several tumor suppressor pathways act on or are activated by STAT3/5 signaling, including tyrosine phosphatases, the sumo ligase Protein Inhibitor of Activated STAT3 (PIAS3), the E3 ubiquitin ligase TATA Element Modulatory Factor/Androgen Receptor-Coactivator of 160 kDa (TMF/ARA160), the miRNAs miR-124 and miR-1181, the Protein of alternative reading frame 19 (p19ARF)/p53 pathway and the Suppressor of Cytokine Signaling 1 and 3 (SOCS1/3) proteins. Cancer mutations and epigenetic alterations may alter the balance between pro-oncogenic and tumor suppressor activities associated with STAT3/5 signaling, explaining their context-dependent association with tumor progression both in human cancers and animal models. |
format | Online Article Text |
id | pubmed-6826753 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68267532019-11-18 STAT3 and STAT5 Activation in Solid Cancers Igelmann, Sebastian Neubauer, Heidi A. Ferbeyre, Gerardo Cancers (Basel) Review The Signal Transducer and Activator of Transcription (STAT)3 and 5 proteins are activated by many cytokine receptors to regulate specific gene expression and mitochondrial functions. Their role in cancer is largely context-dependent as they can both act as oncogenes and tumor suppressors. We review here the role of STAT3/5 activation in solid cancers and summarize their association with survival in cancer patients. The molecular mechanisms that underpin the oncogenic activity of STAT3/5 signaling include the regulation of genes that control cell cycle and cell death. However, recent advances also highlight the critical role of STAT3/5 target genes mediating inflammation and stemness. In addition, STAT3 mitochondrial functions are required for transformation. On the other hand, several tumor suppressor pathways act on or are activated by STAT3/5 signaling, including tyrosine phosphatases, the sumo ligase Protein Inhibitor of Activated STAT3 (PIAS3), the E3 ubiquitin ligase TATA Element Modulatory Factor/Androgen Receptor-Coactivator of 160 kDa (TMF/ARA160), the miRNAs miR-124 and miR-1181, the Protein of alternative reading frame 19 (p19ARF)/p53 pathway and the Suppressor of Cytokine Signaling 1 and 3 (SOCS1/3) proteins. Cancer mutations and epigenetic alterations may alter the balance between pro-oncogenic and tumor suppressor activities associated with STAT3/5 signaling, explaining their context-dependent association with tumor progression both in human cancers and animal models. MDPI 2019-09-25 /pmc/articles/PMC6826753/ /pubmed/31557897 http://dx.doi.org/10.3390/cancers11101428 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Igelmann, Sebastian Neubauer, Heidi A. Ferbeyre, Gerardo STAT3 and STAT5 Activation in Solid Cancers |
title | STAT3 and STAT5 Activation in Solid Cancers |
title_full | STAT3 and STAT5 Activation in Solid Cancers |
title_fullStr | STAT3 and STAT5 Activation in Solid Cancers |
title_full_unstemmed | STAT3 and STAT5 Activation in Solid Cancers |
title_short | STAT3 and STAT5 Activation in Solid Cancers |
title_sort | stat3 and stat5 activation in solid cancers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826753/ https://www.ncbi.nlm.nih.gov/pubmed/31557897 http://dx.doi.org/10.3390/cancers11101428 |
work_keys_str_mv | AT igelmannsebastian stat3andstat5activationinsolidcancers AT neubauerheidia stat3andstat5activationinsolidcancers AT ferbeyregerardo stat3andstat5activationinsolidcancers |